# Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

> **NCT02911298** · PHASE1 · COMPLETED · sponsor: **Tillotts Pharma AG** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation
- **DRUG:** Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation

## Key facts

- **NCT ID:** NCT02911298
- **Lead sponsor:** Tillotts Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-25
- **Primary completion:** 2017-03-06
- **Final completion:** 2017-03-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911298, "Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02911298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*